To evaluate the relationship between lipid content and plaque morphometry as well as the process of lesion progression and regression in patients with significant coronary artery disease.
Introduction
Despite recent advances in medical and interventional therapies, coronary artery disease (CAD) continues to be a major cause of morbidity and mortality. 1 As coronary lesions progress, they evolve into lipid-rich core containing fibroatheromas that are responsible for most acute coronary events. 2, 3 At necropsy, high-risk lesions have a thin fibrous cap overlying a large lipid-rich necrotic core in the setting of an active inflammatory infiltrate. 4, 5 A better understanding of the pathophysiology of the atherosclerotic process as well as the availabitilty of powerful pharmacological agents have permitted consideration of plaque regression and stabilization as a therapeutic goal. Greyscale intravascular ultrasound (IVUS) can determine plaque burden, plaque distribution, and vascular remodelling, but is limited in its ability to estimate plaque composition, including the extent of lipidic plaque. 6 However, intracoronary near-infrared spectroscopy (NIRS) detects lipid-rich plaque (LRP) with high sensitivity and specificity. 7 -12 Recently, the YELLOW (reduction in yellow plaque by aggressive lipid-lowering therapy) trial showed that short-term intensive statin therapy significantly reduced the lipid content of obstructive coronary lesions. 13 The current analysis used the data from the YELLOW trial to explore the relationship among coronary lesion characteristics, the extent of LRP detected by NIRS at baseline, and the short-term impact of statin therapy on LRP.
Methods

Study purpose and subjects
The details of the YELLOW trial have been described previously. 13 In brief, the YELLOW trial was a prospective, randomized, single-centre, and single-blinded trial in which patients with stable CAD and multivessel disease undergoing staged drug-eluting stent implantation for a significant secondary lesion (fractional flow reserve ,0.8) were randomized to intensive statin therapy [rosuvastatin 40 mg/day (AstraZeneca, Cheshire, UK)] vs. standard statin therapy after the primary lesion was treated. We excluded patients with acute coronary syndromes, left main disease, liver disease, serum creatinine .2.0 mg/dL, known hypersensitivity to statins, single-vessel or non-obstructive CAD, and lesions not amenable to percutaneous coronary intervention (PCI). The primary end point of the YELLOW trial was the change in the extent of LRP defined as the 4 mm long segment with the maximum lipid-core burden index (maxLCBI 4mm ) of the secondary lesion between baseline and 6-8 weeks as assessed by NIRS. All patients provided written informed consent. Serial IVUS and NIRS of the secondary lesions were performed after administration of intracoronary nitrates both at baseline (after the first percutaneous intervention) and after 6 -8 weeks (at the time of the staged percutaneous intervention, but before the start of the interventional procedure). The IVUS and NIRS imaging catheters were positioned at least 10 mm distal to the lesion, and automatic pullback was performed at 0.5 mm/s to the aorta. The distal starting points of both IVUS and NIRS imaging were recorded angiographically along with the proximal and distal fiduciary points to assist in registration of the corresponding IVUS and NIRS segments at baseline and follow-up ( Figure 1 ). All image data were archived onto DVD and sent to the blinded intravascular imaging core laboratory of the Cardiovascular Research Foundation (New York, NY, USA) for off-line analysis.
IVUS imaging acquisition and analysis
IVUS was performed using the Eagle Eye 20 MHz, 3.2 Fr, synthetic aperture array catheter (Volcano Corporation, Rancho Cordova, CA, USA) 14 and analysed using the validated planimetry software (echoPlaque, INDEC Medical Systems, Inc., Mountain View, CA, USA). Planar and volumetric quantitative and qualitative analyses were performed according to 
NIRS imaging and analysis
NIRS was performed using a 3.2 Fr NIRS catheter (InfraReDx, Burlington, MA, USA). 13, 15 Raw spectroscopic information was transformed into a probability of LRP that was mapped to a red-to-yellow colour scale, with a low probability of lipid shown as red and a high probability of lipid shown as yellow. Yellow pixels (probability ≥0.6) within the plaque were divided by all viable pixels within the plaque to generate the LCBI, as previously described. 15 The software counted the number of yellow pixels every 0.1 mm, summed the total number of yellow pixels for each possible 4 mm long axial segment, and identified the 4 mm long segment with the maximum LCBI (maxLCBI 4mm ).
Statistical analysis
All data were analysed using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) and JMP version 9.0 (SAS Institute, Inc.). Continuous variables are expressed as mean + SD or median and interquartile range if not normally distributed. Categorical data are presented as numbers and ratios (%). Paired data have been compared using the Student's t-test or the Wilcoxon rank sum test, and intergroup data have been analysed by the one-way analysis of variance (ANOVA) or the Kruskal-Wallis test. Tukey's HSD and Steel -Dwass tests were used for post hoc analysis. Correlations have been evaluated by Spearman rank correlation. Receiver operating characteristic curves have been used to determine the cut-off values of maxLCBI 4mm to discriminate between the small and large LRP groups. For plaque-level data, a model with a generalized estimating equation approach has been used to compensate for any potential cluster effect of multiple plaques in the same individual. Multivariate linear regression analysis has characterized the independent effect of the extent of LRP. A P-value of ,0.05 has been considered statistically significant.
Results
Patient characteristics and lesion analysis
Among 87 patients with stable CAD who were enrolled into the Yellow trial, we included 66 patients in this lesion-level substudy. Twenty-one patients were excluded because of no available paired (baseline and follow-up) NIRS and IVUS data. Patient baseline characteristics are summarized in Table 1 . Mean age was 63.0 + 10.1 years, and 50 were men (76%). The left anterior descending artery was imaged in 46% of patients. Baseline value for low-density lipoprotein cholesterol (LDL-C) was 81.8 + 27.0 mg/dL. Overall, 54 patients (82%) were taking statins at the time of the first procedure. Thirty-one patients were randomized to receive intensive statin therapy (rosuvastatin 40 mg/day), and 35 were randomized to standard lipid-lowering therapy. The LDL-C values in the intensive statin therapy and standard lipid-lowering therapy groups at follow-up were 57.0 + 27.5 mg/dL (P , 0.001 vs. baseline) and 82.9 + 23.5 mg/dL (P ¼ 0.654 vs. baseline), respectively; and the percent changes from baseline were 223.2 + 33.6 and 4.9 + 41.9%, respectively (P ¼ 0.005). Overall, 94 plaques (≥50% plaque burden that was ≥5 mm in length) at baseline were identified. In eight patients, IVUS pullback data were not reliable, and only the MLA and reference site crosssections were analysed. The plaque length and plaque burden assessed by IVUS at baseline were 11.5 + 5.0 mm and 72.1 + 7.2%, respectively. Median maxLCBI 4mm at baseline was 324 (119, 513). The extent of LRP within the maxLCBI 4mm at baseline was positively, albeit weakly, correlated with the IVUS plaque burden at baseline (r ¼ 0.317, P ¼ 0.002). In contrast, the extent of LRP within the maxLCBI 4mm was negatively, albeit weakly, correlated with the IVUS MLA at baseline (r ¼ 20.211, P ¼ 0.040).
Relationship between LRP and plaque morphology
The NIRS maxLCBI 4mm that best identified a large IVUS plaque burden (≥70%) at baseline was 482 (positive predictive value, 100%; negative predictive value, 46%; sensitivity, 39%; specificity, 100%; and area under the curve ¼ 0.696). Furthermore, there was no plaque with a plaque burden of ,70% in combination with a maxLCBI 4mm of ≥500 (large LRP) at baseline ( Figure 2) . The maximum arc of calcium trended towards being greater in plaques with a large plaque burden compared with those with a small plaque burden. The remodelling index was less in plaques with a large plaque burden and a small LCBI compared with either plaques with a small plaque burden and a small LCBI or plaques with a large plaque burden and a large LCBI ( High-sensitivity C-reactive protein (mg/L) 1.9 (0.9, 5.9)
Values are presented as mean + SD or median and interquartile range. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor broker.
Predictors of baseline LRP
We constructed a linear regression model to evaluate predictors of the maxLCBI 4mm . Univariate linear regression analysis revealed that plaque burden, diabetes, and prior myocardial infarction were significantly associated with the maxLCBI 4mm at baseline. Multivariate linear regression modelling demonstrated that the only independent predictors of the baseline maxLCBI 4mm were plaque burden (coefficient, 106; 95% CI, 42-171; P , 0.001; Table 3 ).
Serial NIRS analysis
During the follow-up period (mean 7 weeks), plaque burden at the MLA site did not change from baseline to follow-up (from 72.1 + 7.2 to 71.8 + 8.3%; P ¼ 0.734). On the other hand, the maxLCBI 4mm significantly decreased from 302 (117, 482) to 220 (43, 400) (P ¼ 0.022). Among the 20 plaques with a large plaque burden and a large amount of LRP at baseline, a decrease in LRP was identified in all of the plaques receiving intensive statin therapy without a change in plaque burden. The maxLCBI 4mm in these 11 plaques significantly decreased from 703 (525, 749) to 399 (336, 532), P ¼ 0.004; and the median change in maxLCBI 4mm was 2202. However, this was true only in patients treated with intensive statin therapy and not in patients treated with standard statin therapy ( Figure 3) . When significant regression in maxLCBI 4mm was defined as a decrease of .200, the best cut-off value of the maxLCBI 4mm at baseline for predicting significant LRP regression was 262 (sensitivity, 100%; specificity, 57%; and area under the curve ¼ 0.832); and the best cut-off in plaque burden at baseline for predicting significant LRP regression was 70% (sensitivity, 86%; specificity, 38%; and area under the curve ¼ 0.541).
Discussion
In the present study, we found that coronary plaques containing a large lipidic core had a large plaque burden (≥70%) compared with those containing a small amount of LRP. In contrast, there was no plaque having a plaque burden of ,70%, but a large amount of LRP.
Consequently, plaque burden was the best indicator of the extent of LRP in significant coronary lesions. Furthermore, our serial plaquelevel analysis demonstrated that intensive statin therapy reduced lipid content without changing plaque burden in lesions with a large plaque burden and a large amount of LRP at baseline.
LRP and lesion morphology and the process of plaque progression
The size of the lipid-rich necrotic core, positive remodelling, and fibrous cap thickness are critical morphological features that distinguish unstable high-risk plaques and plaque ruptures from earlier progressive lesions. As a plaque progresses from early atherosclerosis to a fibroatheroma, the free cholesterol content of the lesion increases. 16, 17 Vascular remodelling is a fundamental component of this process. 18 Burke et al. 19 reported that positive remodelling was associated with an increase in the size of the lipid-rich core, development of a thin-cap fibroatheroma, and intraplaque haemorrhage. These pathologic observations were supported by in vivo studies using radiofrequency IVUS, optical coherence tomography, and NIRS. 10, 20 In the current study, coronary plaques containing a large lipidic core had a higher remodelling index compared with those containing a small amount of LRP. The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study 14 showed that nonculprit lesions associated with subsequent coronary events were characterized by a large plaque burden (≥70%), small MLA (≤4.0 mm 2 ), and a thin-cap fibroatheroma by radiofrequency IVUS. Pu et al. 15 showed a positive relationship between the NIRSderived LCBI and percent necrotic core estimated by radiofrequency IVUS in non-calcified plaques. Madder et al. 21 recently reported that the maxLCBI 4mm in culprit segments of patients with ST-elevation myocardial infarction was significantly higher than in non-culprit segments of the culprit vessel. Goldstein et al. 22 reported that PCI of lesions with a maxLCBI 4mm of ≥500 was associated with a 50% risk of peri-procedural myocardial infarction. Accordingly, coronary plaques categorized as having a large plaque burden with a large amount of LRP in the present study were consistent with a high-risk unstable lesion phenotype.
Lipid-lowering therapy and intravascular imaging trials for plaque progression and regression
Lipid-lowering strategies, particularly statins, have become the cornerstone of the prevention and treatment of cardiovascular disease. Cardiovascular outcomes and the occurrence of acute coronary events depend not only on the severity of luminal narrowing, but also on plaque burden and plaque characteristics. 14 So far IVUS has evolved as the imaging modality that generates precise volumetric quantification of coronary atherosclerosis. By measuring the change in plaque burden over time, IVUS can evaluate the potential antiatherosclerotic efficacy of pharmacological interventions. 23 Serial IVUS trials have shown that intensive statin therapy slows the progression of coronary atherosclerosis and may even result in disease regression. 24, 25 In the present study, three quarters of patients were already taking statins at baseline, the mean baseline LDL-cholesterol levels were ,100 mg/dL, and the mean follow-up LDL-cholesterol levels were 70 mg/dL (rate of statin use, 91%). Previous statin treatment might have affected lesions resistant to plaque volume regression. In addition, follow-up period may have affected the findings in the current study since the period of our study was only 7 weeks while treatment periods in most of the IVUS progression-regression trials have been at least 6-12 months. 26, 27 Nevertheless, the efficacy of intensive statin therapy (a decrease in LRP, especially in the setting of a large amount of lipidic plaque at baseline) was observed by NIRS, but without a change in plaque burden as observed by IVUS. Williams et al. suggested that regression is not merely a reversal of progression, but instead involves emigration of the maladaptive macrophage infiltrate, followed by initiation of a stream of healthy, normally functioning phagocytes that mobilize necrotic debris and all other components of advanced plaques. 28 A previous animal study reported that the early phase of regression showed loss of foam cells from the lesions and an increase in non-foam cell macrophages around areas of necrosis. Long term, the necrotic areas virtually disappeared, indicating removal of the material by an influx of functioning, healthy phagocytes. 29 Serial angioscopic patient studies have also indicated that plaque stabilization was observed without a reduction of IVUS plaque burden following statin treatment. 30 In addition, the YELLOW trial showed that short-term intensive statin treatment appeared to reduce lipid content as assessed by NIRS without any change in lesion severity as assessed by fractional flow reserve (FFR). 13 Thus, evaluation by NIRS might be a clinically useful index of plaque compositional change in the assessment of residual high-risk LRPs in statin-treated patients compared with conventional plaque estimation by IVUS and physiological measurements by fractional flow reserve, especially when co-registered to IVUS assessment of plaque burden that is now possible in a single catheter.
Limitations
The present study had several limitations. First, the present study included a small number of patients and a short duration of follow-up. Secondly, the NIRS lipid composition data and the IVUS plaque burden data were obtained by separate catheters that were co-registered according to angiographic geographic markers. We relied on coronary angiography to facilitate co-registration of IVUS and NIRS images; a new NIRS catheter has been developed to simultaneously acquire NIRS and IVUS data. Thirdly, we only focused on lesions having haemodynamic significance (FFR ,0.8) with angiographic diameter stenosis .70% and only studied a single lesion at baseline and at follow-up. Ideally, multiple lesions should be studied. Finally, the majority of patients were taking statins at baseline and therefore, the current findings may not apply to statin naive patients.
Conclusion
The present study demonstrated an important relationship between NIRS determined LRPs and plaque morphometry in patients who had clinically significant atherosclerotic plaques. Coronary lesions containing a large amount of LRP also had a large plaque burden (≥70%). In our serial NIRS findings, short-term regression of LRP (without a change in plaque burden) was observed mainly in plaques with a large plaque burden and a large amount of LRP at baseline.
